Drugs / Supaglutide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05694221 | Mar → Jun 2023 | — | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03745885 | Dec 2018 → Jun 2019 | type 2 diabetes mellitus | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04314622 | Apr → Oct 2020 | type 2 diabetes mellitus | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04994288 | Aug 2021 → Jun 2023 | type 2 diabetes mellitus | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Supaglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05694221 ↗ |
| Action | Activate | “as a novel glucagon-like peptide-1 receptor agonist” PMID 40587051 ↗ Jun 2025 |
| Route | Subcutaneous | “Administered SC in the Supaglutide arms.” NCT03745885 ↗ |